Xinjiang Baihuacun Co Ltd Asset Resilience Ratio

Latest as of March 2026: 21.23%

Xinjiang Baihuacun Co Ltd asset resilience ratio. Xinjiang Baihuacun Co Ltd (600721) has an Asset Resilience Ratio of 21.23% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Xinjiang Baihuacun Co Ltd to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥232.08 Million
≈ $33.96 Million USD Cash + Short-term Investments

Total Assets

CN¥1.09 Billion
≈ $159.97 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of Xinjiang Baihuacun Co Ltd (1996–2020)

Asset resilience ratio of Xinjiang Baihuacun Co Ltd from 1996 to 2020. This chart shows how Xinjiang Baihuacun Co Ltd's Asset Resilience Ratio has changed over time. Read Xinjiang Baihuacun Co Ltd (600721) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Xinjiang Baihuacun Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 600721 total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥232.08 Million 21.23%
Total Liquid Assets CN¥232.08 Million 21.23%

Asset Resilience Insights

  • Good Liquidity Position: Xinjiang Baihuacun Co Ltd maintains a healthy 21.23% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Xinjiang Baihuacun Co Ltd Industry Peers by Asset Resilience Ratio

Compare Xinjiang Baihuacun Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Brinker International Inc
NYSE:EAT
Restaurants 0.55%
BJs Restaurants Inc
NASDAQ:BJRI
Restaurants 0.00%
Collins Foods Ltd
AU:CKF
Restaurants 0.06%
Sapphire Foods India Limited
NSE:SAPPHIRE
Restaurants 0.10%
Greggs PLC
LSE:GRG
Restaurants 8.63%
Mr. Onion
TWO:2740
Restaurants -1.02%
TDH Holdings Inc
NASDAQ:PETZ
Restaurants 36.06%
Heavitree Brewery A
LSE:HVTA
Restaurants -5.90%

Xinjiang Baihuacun Co Ltd Asset Resilience Ratio by Year (1996–2020)

Xinjiang Baihuacun Co Ltd asset resilience ratio by year from 1996 to 2020. The table below shows the annual Asset Resilience Ratio data for Xinjiang Baihuacun Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2020-12-31 1.03% CN¥10.00 Million
≈ $1.46 Million
CN¥974.68 Million
≈ $142.63 Million
-2.46pp
2019-12-31 3.49% CN¥45.00 Million
≈ $6.58 Million
CN¥1.29 Billion
≈ $188.94 Million
+0.30pp
2018-12-31 3.18% CN¥39.73 Million
≈ $5.81 Million
CN¥1.25 Billion
≈ $182.67 Million
+3.01pp
1998-12-31 0.17% CN¥818.00K
≈ $119.70K
CN¥477.66 Million
≈ $69.90 Million
-0.07pp
1997-12-31 0.25% CN¥974.97K
≈ $142.67K
CN¥396.05 Million
≈ $57.95 Million
-0.70pp
1996-12-31 0.95% CN¥4.42 Million
≈ $647.37K
CN¥465.42 Million
≈ $68.11 Million
--
pp = percentage points

About Xinjiang Baihuacun Co Ltd

SHG:600721 China Restaurants
Market Cap
$553.15 Million
CN¥3.78 Billion CNY
Market Cap Rank
#11325 Global
#3089 in China
Share Price
CN¥9.83
Change (1 day)
+9.96%
52-Week Range
CN¥6.50 - CN¥16.68
All Time High
CN¥20.70
About

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd engages in pharmaceutical research and development, clinical trials, biomedicine, commercial properties, and other businesses. It also offers comprehensive contract research organization (CRO) solutions, including one-stop, full-process services for drug R&D, such as Phase I to IV clinical trials, bioequivalence and pharmacokinetics testing, medical scienc… Read more